Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 31.52
TARO's Cash to Debt is ranked higher than
77% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. TARO: 31.52 )
TARO' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 31.52

Equity to Asset 0.78
TARO's Equity to Asset is ranked higher than
81% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. TARO: 0.78 )
TARO' s 10-Year Equity to Asset Range
Min: 0.23   Max: 0.81
Current: 0.78

0.23
0.81
F-Score: 6
Z-Score: 13.20
M-Score: -2.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 48.97
TARO's Operating margin (%) is ranked higher than
99% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.69 vs. TARO: 48.97 )
TARO' s 10-Year Operating margin (%) Range
Min: -27.89   Max: 48.97
Current: 48.97

-27.89
48.97
Net-margin (%) 39.68
TARO's Net-margin (%) is ranked higher than
97% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.54 vs. TARO: 39.68 )
TARO' s 10-Year Net-margin (%) Range
Min: -32.77   Max: 39.68
Current: 39.68

-32.77
39.68
ROE (%) 30.03
TARO's ROE (%) is ranked higher than
99% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.81 vs. TARO: 30.03 )
TARO' s 10-Year ROE (%) Range
Min: -166.08   Max: 38.92
Current: 30.03

-166.08
38.92
ROA (%) 24.06
TARO's ROA (%) is ranked higher than
99% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. TARO: 24.06 )
TARO' s 10-Year ROA (%) Range
Min: -19.47   Max: 24.06
Current: 24.06

-19.47
24.06
ROC (Joel Greenblatt) (%) 102.44
TARO's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.46 vs. TARO: 102.44 )
TARO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -31.82   Max: 102.44
Current: 102.44

-31.82
102.44
Revenue Growth (%) 19.60
TARO's Revenue Growth (%) is ranked higher than
86% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. TARO: 19.60 )
TARO' s 10-Year Revenue Growth (%) Range
Min: -6.8   Max: 34.7
Current: 19.6

-6.8
34.7
EBITDA Growth (%) 56.80
TARO's EBITDA Growth (%) is ranked higher than
97% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. TARO: 56.80 )
TARO' s 10-Year EBITDA Growth (%) Range
Min: -24.3   Max: 56.8
Current: 56.8

-24.3
56.8
EPS Growth (%) 24.50
TARO's EPS Growth (%) is ranked higher than
86% of the 504 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.10 vs. TARO: 24.50 )
TARO' s 10-Year EPS Growth (%) Range
Min: 0   Max: 102.1
Current: 24.5

0
102.1
» TARO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

TARO Guru Trades in Q1 2013

Jim Simons 125,400 sh (+45.81%)
» More
Q2 2013

TARO Guru Trades in Q2 2013

Jim Simons 163,200 sh (+30.14%)
» More
Q3 2013

TARO Guru Trades in Q3 2013

Steven Cohen 5,644 sh (New)
HOTCHKIS & WILEY 438,675 sh (New)
Jim Simons 213,100 sh (+30.58%)
» More
Q4 2013

TARO Guru Trades in Q4 2013

HOTCHKIS & WILEY 529,936 sh (+20.8%)
Jim Simons 235,473 sh (+10.5%)
Steven Cohen 4,701 sh (-16.71%)
» More
» Details

Insider Trades

Latest Guru Trades with TARO



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 14.50
TARO's P/E(ttm) is ranked higher than
86% of the 527 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.50 vs. TARO: 14.50 )
TARO' s 10-Year P/E(ttm) Range
Min: 3.14   Max: 477.06
Current: 14.5

3.14
477.06
P/B 5.10
TARO's P/B is ranked lower than
56% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. TARO: 5.10 )
TARO' s 10-Year P/B Range
Min: 1.07   Max: 6.23
Current: 5.1

1.07
6.23
P/S 6.40
TARO's P/S is ranked lower than
67% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. TARO: 6.40 )
TARO' s 10-Year P/S Range
Min: 0.61   Max: 7.28
Current: 6.4

0.61
7.28
PFCF 14.40
TARO's PFCF is ranked higher than
87% of the 327 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.50 vs. TARO: 14.40 )
TARO' s 10-Year PFCF Range
Min: 4.51   Max: 27.78
Current: 14.4

4.51
27.78
EV-to-EBIT 10.90
TARO's EV-to-EBIT is ranked higher than
85% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.43 vs. TARO: 10.90 )
TARO' s 10-Year EV-to-EBIT Range
Min: 4.7   Max: 59.6
Current: 10.9

4.7
59.6
PEG 0.30
TARO's PEG is ranked higher than
97% of the 309 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.87 vs. TARO: 0.30 )
TARO' s 10-Year PEG Range
Min: 0.3   Max: 36.64
Current: 0.3

0.3
36.64
Shiller P/E 26.70
TARO's Shiller P/E is ranked higher than
65% of the 363 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.45 vs. TARO: 26.70 )
TARO' s 10-Year Shiller P/E Range
Min: 6.13   Max: 83.05
Current: 26.7

6.13
83.05

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.00
TARO's Price/Net Cash is ranked lower than
53% of the 215 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.80 vs. TARO: 15.00 )
TARO' s 10-Year Price/Net Cash Range
Min: 6.83   Max: 92.19
Current: 15

6.83
92.19
Price/Net Current Asset Value 8.00
TARO's Price/Net Current Asset Value is ranked higher than
61% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.10 vs. TARO: 8.00 )
TARO' s 10-Year Price/Net Current Asset Value Range
Min: 4.1   Max: 82.69
Current: 8

4.1
82.69
Price/Tangible Book 5.00
TARO's Price/Tangible Book is ranked lower than
53% of the 638 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. TARO: 5.00 )
TARO' s 10-Year Price/Tangible Book Range
Min: 0.89   Max: 15.98
Current: 5

0.89
15.98
Price/DCF (Projected) 2.10
TARO's Price/DCF (Projected) is ranked higher than
63% of the 349 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. TARO: 2.10 )
TARO' s 10-Year Price/DCF (Projected) Range
Min: 1.4   Max: 201.56
Current: 2.1

1.4
201.56
Price/Median PS Value 3.10
TARO's Price/Median PS Value is ranked lower than
74% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. TARO: 3.10 )
TARO' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 4.33
Current: 3.1

0.18
4.33
Price/Graham Number 1.80
TARO's Price/Graham Number is ranked higher than
66% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.20 vs. TARO: 1.80 )
TARO' s 10-Year Price/Graham Number Range
Min: 0.4   Max: 10.12
Current: 1.8

0.4
10.12
Earnings Yield (Greenblatt) 9.20
TARO's Earnings Yield (Greenblatt) is ranked higher than
87% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. TARO: 9.20 )
TARO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.7   Max: 21.1
Current: 9.2

1.7
21.1
Forward Rate of Return (Yacktman) 0.88
TARO's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.22 vs. TARO: 0.88 )
TARO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -31.7   Max: 56.6
Current: 0.88

-31.7
56.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Taro Pharmaceutical Industries Ltd develops, manufactures & markets prescription & over-the-counter (OTC) pharmaceutical products & active pharmaceutical ingredients (APIs) for use in its finished dosage form products.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide